PDCD2L

Across TCGA pan-cancer cohorts, PDCD2L RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of PDCD2L’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where PDCD2L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PDCD2L is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

COAD, LUAD, and BLCA are the cancer types where PDCD2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDCD2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	+2.191	<.001	12	view →
LUAD	Male	III,IV	+1.525	<.001	11	view →
BLCA	All	All	+1.013	<.001	11	view →
LIHC	Male	II,III,IV	+1.315	<.001	9	view →
STAD	Male	II,III,IV	+1.235	<.001	9	view →
KIRC	All	III,IV	+0.318	<.001	9	view →
LUSC	All	II,III,IV	+1.377	<.001	8	view →
HNSC	Male	IV	+1.147	<.001	8	view →
READ	All	All	+1.308	<.001	7	view →
KIRP	All	II,III,IV	+0.726	<.001	7	view →
UCEC	All	III,IV	+0.853	<.001	6	view →
BRCA	All	III,IV	+0.577	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

PDCD2L–COAD

Open the COAD breakdown →